ArticleStem cells translational medicine2013
Podocalyxin is a glycoprotein ligand of the human pluripotent stem cell-specific probe rBC2LCN.
Article in Stem cells translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- The endo-lysosomal system drives lumen formation in a human epiblast model.Nature communications · 2026Article
- Structural and functional characterization of the newly identified Photorhabdus laumondii tumor necrosis factor-like lectin.The FEBS journal · 2026Article
- Glycan Markers of Pluripotent Stem Cells.Advances in experimental medicine and biology · 2026Review
- Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.Nature communications · 2024Article
- Glycan Modifications as Regulators of Stem Cell Fate.Biology · 2024Review
- Lower Levels of GABAergic Function Markers in Corticotropin-Releasing Hormone-Expressing Neurons in the sgACC of Human Subjects With Depression.Frontiers in psychiatry · 2022Article
- Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells.Cancer science · 2021Article
- Integrated analysis of glycan and RNA in single cells.iScience · 2021Article
- rBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma.FEBS open bio · 2020Article
- A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin.Regenerative therapy · 2020Article
- Application of Lectin Microarrays for Biomarker Discovery.ChemistryOpen · 2020Review
- BC2L-C N-Terminal Lectin Domain Complexed with Histo Blood Group Oligosaccharides Provides New Structural Information.Molecules (Basel, Switzerland) · 2020Article
- Effect of mechanical vibration stress in cell culture on human induced pluripotent stem cells.Regenerative therapy · 2019Article
- An Integrated Pan-Cancer Analysis and Structure-Based Virtual Screening of GPR15.International journal of molecular sciences · 2019Article
- Transplantation of Mouse Induced Pluripotent Stem Cell-Derived Podocytes in a Mouse Model of Membranous Nephropathy Attenuates Proteinuria.Scientific reports · 2019Article
- Glycan Markers of Human Stem Cells Assigned with Beam Search Arrays.Molecular & cellular proteomics : MCP · 2019Article
- Increased Expression of Cell Surface SSEA-1 is Closely Associated with Naïve-Like Conversion from Human Deciduous Teeth Dental Pulp Cells-Derived iPS Cells.International journal of molecular sciences · 2019Article
- Elucidation of the enigma of glycosphingolipids in the regulation of inflammation and degeneration - Great progress over the last 70 years.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2019Review
- Glycome analysis of extracellular vesicles derived from human induced pluripotent stem cells using lectin microarray.Scientific reports · 2018Article
- Automated adherent cell elimination by a high-speed laser mediated by a light-responsive polymer.Communications biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In comprehensive glycome analysis with a high-density lectin microarray, we have previously shown that the recombinant N-terminal domain of the lectin BC2L-C from Burkholderia cenocepacia (rBC2LCN) binds exclusively to undifferentiated human induced pluripotent stem (iPS) cells and embryonic stem (ES) cells but not to differentiated somatic cells. Here we demonstrate that podocalyxin, a heavily glycosylated type 1 transmembrane protein, is a glycoprotein ligand of rBC2LCN on human iPS cells and ES cells. When analyzed by DNA microarray, podocalyxin was found to be highly expressed in both iPS cells and ES cells. Western and lectin blotting revealed that rBC2LCN binds to podocalyxin with a high molecular weight of more than 240 kDa in undifferentiated iPS cells of six different origins and four ES cell lines, but no binding was observed in either differentiated mouse feeder cells or somatic cells. The specific binding of rBC2LCN to podocalyxin prepared from a large set of iPS cells (138 types) and ES cells (15 types) was also confirmed using a high-throughput antibody-overlay lectin microarray. Alkaline digestion greatly reduced the binding of rBC2LCN to podocalyxin, indicating that the major glycan ligands of rBC2LCN are presented on O-glycans. Furthermore, rBC2LCN was found to exhibit significant affinity to a branched O-glycan comprising an H type 3 structure (Ka, 2.5 × 10(4) M(-1)) prepared from human 201B7 iPS cells, indicating that H type 3 is a most probable potential pluripotency marker. We conclude that podocalyxin is a glycoprotein ligand of rBC2LCN on human iPS cells and ES cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.